Allografts are human donor tissues (e.g. bone) processed for use in orthopaedic, dental and trauma procedures (e.g. spinal, pelvic and fracture non-union).

These products can be cleaned and processed via methods based on eCOO® Technology. Subsequent sterilisation of these products can be achieved again by eCOO® Technology-based sterilisation or other conventional methods.

eTiss® allograft products include eTiss® bone void fillers, ideally suited for a multitude of orthopaedic applications and exhibiting excellent osteoconductivity, eTiss® Demineralised Bone Matrix (DBM), typically used in complex fractures and spinal fusion and eTiss® soft tissue allografts (e.g. tendons), used as a replacement of ruptured tendons after sports-related injuries and particularly benefiting from the retained tensile strength.
eTiss® allografts can, in the near future, be further enhanced by EMCM’s eCOO® Plus technology, enabling controlled release of API’s.

Main advantages include:

  • Lower risk of transmitting diseases than the products currently available
  • Retain of mechanical properties of the eTiss® allografts
  • Excellent osteoconductive and inductive properties
  • SAL 6 sterility
  • Controlled delivery of APIs

For scientific data, please click here.

Most of the products developed at EMCM under the eTiss® family are classified as Human Tissue (Allografts), as per the EU directives, and are available for distribution in most European countries:


The above product portfolio is provided to bone and tissue banks & medtech companies alike, either as a finished product or as a contracted service.

EMCM is currently in the process of registration of its techniques and products in Europe, the Middel-East and Latin/South America.  

Due to host material, scientific and technical limitations, all advantages of the eCOO® Technology platform may not be applicable to each product under eTiss®, eColl® & eNova® products.